Added to YB: 2026-05-29
Pitch date: 2026-05-26
SRT3.DE [neutral]
Sartorius Aktiengesellschaft
+1.51%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell culture solutions, including bioreactors and fermenters, cell culture reagents, supplements and matrices, nucleic acid and delivery solutions, cell culture media, and cell lines and buffers; and fluid management products.
Market Cap
EUR 14.5B
Pitch Price
EUR 185.60
Price Target
N/A
Dividend
0.31%
EV/EBITDA
20.60
P/E
N/A
EV/Sales
5.45
Sector
Life Sciences Tools and Services
Category
growth
Sartorius (SRT3 Germany): 2026 still the bridge year before a fuller normalisation
SRT3.DE (update): Bioprocessing market structurally healthy, 8-10% annual growth expected. Consumables solid (85% of BPS rev vs normal 80%), equipment orders stabilizing Q2/Q3 after mid-single-digit Q1 decline, targeting flat YoY 2026. Single-use tech <20% penetration in commercial mfg vs >85% clinical = long runway. Downstream bottleneck addressed via Pionic platform. BPS guide: 9-12% growth, outpacing market ~150bp/yr.
Read full article (2 min)